Effects of administration of dopamine D2 agonist quinpirole on exploratory locomotion.
Injections of the dopamine D2 agonist quinpirole (LY 171555) into the nucleus accumbens reduced exploratory locomotion in a dose-dependent manner. Injections of the dopamine D1 agonist SKF 38393 had no effect on exploratory locomotion. The results are consistent with observations from recent electrophysiological and behavioral experiments which suggest a presynaptic action of the D2 agonist. It is proposed that quinpirole activates D2 receptors on the axon terminals of glutamatergic hippocampal-accumbens neurons that are associated with exploratory locomotion.
Mogenson
G J
GJ
Department of Physiology, University of Western Ontario, London, Canada.
Wu
M
M
D000818:Animals; D015259:Dopamine Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004873:Ergolines / Q000494:pharmacology*; D005106:Exploratory Behavior / Q000187:drug effects*; D008297:Male; D009043:Motor Activity / Q000187:drug effects*; D019257:Quinpirole; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D015259:Dopamine Agents; D004873:Ergolines; D019257:Quinpirole